Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation

Background and Objectives: The US Food and Drug Administration (FDA) defines a biomarker as a characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention. Biomarkers may be used in clinical care or as drug developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey, Kinney, Jefferson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318582/
https://www.ncbi.nlm.nih.gov/pubmed/35888671
http://dx.doi.org/10.3390/medicina58070952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318582/
https://www.ncbi.nlm.nih.gov/pubmed/35888671
http://dx.doi.org/10.3390/medicina58070952

Ejemplares similares